Balyasny Asset Management’s Immunogen Inc IMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-1,496,758
Closed -$44.4M 3257
2023
Q4
$44.4M Buy
1,496,758
+1,484,838
+12,457% +$29.6M 0.08% 301
2023
Q3
$189K Sell
11,920
-1,020,659
-99% -$17M ﹤0.01% 2042
2023
Q2
$19.5M Buy
1,032,579
+929,828
+905% +$11M 0.04% 544
2023
Q1
$395K Sell
102,751
-284,043
-73% -$1.21M ﹤0.01% 2020
2022
Q4
$1.92M Buy
+386,794
New +$2.1M 0.01% 1449
2022
Q3
Sell
-109,741
Closed -$493K 3374
2022
Q2
$493K Buy
+109,741
New +$477K ﹤0.01% 1982
2021
Q3
Sell
-191,876
Closed -$1.26M 2535
2021
Q2
$1.26M Buy
+191,876
New +$1.34M 0.01% 1180
2019
Q2
Sell
-430,328
Closed -$1.17M 1792
2019
Q1
$1.17M Buy
430,328
+177,243
+70% +$768K 0.01% 975
2018
Q4
$1.22M Buy
+253,085
New +$1.54M 0.01% 848
2018
Q2
Sell
-68,023
Closed -$716K 2240
2018
Q1
$716K Buy
68,023
+43,045
+172% +$425K ﹤0.01% 1340
2017
Q4
$160K Buy
+24,978
New +$154K ﹤0.01% 1938
2016
Q3
Sell
-22,222
Closed -$68K 1330
2016
Q2
$68K Buy
+22,222
New +$139K ﹤0.01% 1108

Other funds holding IMGN

Balyasny Asset Management's IMGN Position: Q1 2024 in Review

Balyasny Asset Management sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 1,496,758 shares — an estimated $44.4M sold.

Balyasny Asset Management first reported a position in IMGN in Q2 2016 and held it in 12 quarters. The position peaked at $44.4M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Balyasny Asset Management reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 1,496,758 Immunogen Inc shares in Q1 2024, an estimated $44.4M.
  • Balyasny Asset Management first reported a position in Immunogen Inc in Q2 2016 and held it in 12 quarters.
  • Balyasny Asset Management's Immunogen Inc position peaked at $44.4M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.